Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
SSI Strategy acquisition of NDA Group
We advised SSI Strategy on the acquisition
Gracell Biotechnologies PIPE of ordinary shares and warrants
The company’s ADSs are listed on Nasdaq
Recursion Pharmaceuticals $300 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
NGM Biopharmaceuticals $100 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Allurion Technologies merger with Compute Health Acquisition
We advised the capital markets adviser on the de-SPAC transaction
Immedica Pharma acquisition of pegzilarginase assets from Aeglea
We advised Immedica on the transaction
BMS $35 million investment in Immatics
We advised Immatics on the private placement of ordinary shares
Korro Bio $117 million private placement
The financing is expected to close immediately prior to the completion of Korro Bio’s merger with Frequency Therapeutics
Bausch + Lomb $1.75 billion financing for acquisition of certain Novartis assets
We are advising Bausch + Lomb on the financing
Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing